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BACKGRound: In Canada, more than 70% of new cases of hepati-
tis C virus (HCV) infection per year involve injection drug users 
(IDUs) and, currently, there is no consensus on how to offer them 
medical care. 
oBJeCtive: To examine the characteristics of Canadian specialist 
physicians and their likelihood to provide treatment to HCV patients 
who are IDUs.
Methods: A nationwide, cross-sectional study was conducted in the 
specialty areas of hepatology, gastroenterology and infectious diseases 
to examine HCV services. The questionnaire requested information 
regarding basic demographics, referral pathways and opinions (yes/no), 
and examined how a physician’s treatment regimen is influenced by 
factors such as treatment eligibility, HCV care management and barri-
ers to providing quality service.
Results: Despite the fact that the majority of prevalent and inci-
dent cases of HCV are associated with injection drug use, very few 
specialist physicians actually provide the necessary therapy to this 
population. Only 19 (19.79%) comprehensive service providers were 
likely to provide treatment to a current IDU who uses a needle 
exchange on a regular basis. The majority of comprehensive service 
providers (n=86 [89.58%]) were likely to provide treatment to a for-
mer IDU who was stable on substitution therapy. On bivariate analy-
sis, factors associated with the likelihood to provide treatment to 
current IDUs included physicians’ type, ie, infectious disease specialists 
compared with noninfectious specialists (OR 3.27 [95% CI 1.11 to 9.63]), 
and the size of the community where they practice (OR 4.16 [95% CI 
1.36 to 12.71] [population 500,000 or greater versus less than 
500,000]). Results of the multivariate logistic regression analysis were 
largely consistent with the results observed in the bivariate analyses. 
After controlling for other confounding variables, only community size 
was significantly associated with providing treatment to current IDUs 
(OR 3.89 [95% CI 1.06 to 14.26] [population 500,000 or greater versus 
less than 500,000]).
ConClusion: The present study highlighted the reluctance of 
specialists to provide treatment to current IDUs infected with HCV. 
Providing treatment services for HCV-infected substance abusers is 
challenging and there are many treatment barriers. However, effective 
delivery of treatment to this population will help to limit the spread of 
HCV. The present study clearly identified a need for improved HCV 
treatment accessibility for IDUs.
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les attitudes et la pratique des médecins envers le 
traitement des consommateurs de drogues par 
injection infectés par le virus de l’hépatite C :  
les résultats d’un sondage national auprès de 
spécialistes du Canada
histoRiQue : Au Canada, plus de 70 % des nouveaux cas d’infection 
par le virus de l’hépatite C (VHC) par année sont des consommateurs de 
drogues injectables (CDI). Il n’y a pas de consensus pour l’instant sur la 
manière de leur offrir des soins médicaux.
oBJeCtiF : Examiner les caractéristiques des médecins spécialistes 
canadiens et la probabilité qu’ils dispensent un traitement aux patients 
ayant un VHC qui sont des CDI.
MÉthodoloGie : Les chercheurs ont mené une étude transversale 
nationale dans les domaines de spécialité de l’hépatologie, de la gastroen-
térologie et de l’infectiologie afin d’examiner les services sur le VHC. Le 
questionnaire comprenait des questions sur les données démographiques 
de base, les voies d’aiguillage et les opinions (oui ou non) et permettait 
d’évaluer à quel point le schéma thérapeutique d’un médecin est influ-
encé par des facteurs comme l’admissibilité au traitement, la prise en 
charge des soins du VHC et les obstacles à offrir des services de qualité.
RÉsultAts : Même si la majorité des cas prévalents et incidents de 
VHC s’associent à la consommation de drogues injectables, très peu de 
médecins spécialistes dispensent la thérapie nécessaire à cette popula-
tion. Seulement 19 (19,79 %) dispensateurs de soins complets étaient sus-
ceptibles de traiter un CDI qui utilise des services d’échange de seringues 
sur une base régulière. La majorité des dispensateurs de soins complets 
(n=86 [89,58 %]) étaient susceptibles de traiter un ancien CDI stabilisé 
par un traitement de substitution. D’après l’analyse bivariée, les facteurs 
associés à la probabilité de dispenser un traitement aux CDI incluaient le 
type de médecin, c’est-à-dire les spécialistes en infectiologie par rapport 
aux autres spécialistes (RRR 3,27 [95 % IC 1,11 à 9,63]) et la dimension 
de la collectivité où ils exercent (RRR 4,16 [95 % IC 1,36 à 12,71] 
[population de 500 000 habitants ou plus par rapport à population de 
moins de 500 000 habitants]). Les résultats de l’analyse de régression 
logistique multivariée étaient largement conformes à ceux observés dans 
les analyses bivariées. Après contrôle des autres variables confusion-
nelles, seule la dimension de la collectivité avait un lien significatif avec 
l’administration d’un traitement aux CDI (RRR 3,89 [95 % IC 1,06 à 
14,26] [population de 500 000 habitants ou plus par rapport à population 
de moins de 500 000 habitants]).
ConClusion : La présente étude a fait ressortir l’hésitation à dis-
penser un traitement aux CDI infectés par le VHC. Il est difficile d’offrir 
des services thérapeutiques aux consommateurs de drogues infectés par le 
VIH, et on constate beaucoup d’obstacles au traitement. Cependant, la 
prestation efficace du traitement à cette population contribuera à limiter la 
propagation du VHC. La présente étude a clairement établi la nécessité 
d’améliorer l’accessibilité au traitement du VHC pour les CDI.
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I njection drug use is the leading risk factor for hepatitis C virus (HCV) infection in industrialized countries (1,2). The risk of trans-
mission is associated with sharing injection equipment including nee-
dles, syringes, spoons, cottons and other injection paraphernalia (3). 
Several recent studies (4-7) have shown that injection drug users 
(IDUs) can be treated effectively, with treatment success rates that are 
similar to other patients. Nevertheless, treatment rates are low, and it 
has been suggested that only approximately 10% of HCV-infected 
IDUs who are possible candidates for treatment are actually treated 
(8-9). It has also been shown that 70% to 80% of HCV-infected IDUs 
have expressed interest in being treated (10,11).
Currently, North American guidelines (12) state that treatment for 
HCV should be considered on a case-by-case basis and that it is not 
justifiable to exclude HCV-infected IDUs from antiviral therapy. 
However, there is no clear understanding of the associated factors that 
determine whether a specialist will provide treatment to HCV-infected 
substance abusers. To develop comprehensive strategies to address the 
HCV epidemic, it is important to understand physician criteria associ-
ated with HCV-related practice patterns. Thus, an inaugural nation-
wide survey was conducted to examine HCV treatment eligibility 
criteria for physicians trained in the specialties of infectious diseases, 
gastroenterology and hepatology. This particular group represents the 
majority of physicians providing treatment to people living with HCV.
The objectives of the present study were to describe the clinical 
practice patterns in treating HCV-infected IDUs and to examine the 
factors that influence a specialist’s likelihood to provide treatment to 
HCV-infected IDUs.
Methods
study design and participants
The present study included 528 medical specialists who were most 
likely to provide care to patients with HCV infection. The sample was 
obtained using the following two approaches. First, a comprehensive 
search of the most recent version of the Canadian Medical Directory 
on CD-ROM [13], which contains information for approximately 
61,000 currently practising Canadian physicians, was undertaken. 
Based on their practices, physicians were grouped according to their 
main specialties (one or more). The Canadian Medical Directory 
allows searches of up to 60 specialties (eg, cardiology and rheumatol-
ogy) and 45 subspecialties (eg, diabetes, pain management and hepa-
tology). Thus, a systematic search was conducted in the specialties of 
gastroenterology, infectious diseases, endocrinology and pediatrics, 
searching for text with any mention of hepatology, hepatitis or liver 
disease in their specialty description. Second, because it was likely that 
gastroenterologists (GIs) or infectious disease specialists (IDs) treating 
HCV may be missed in a key word search, it was decided to also 
include everyone under these two categories even though some of 
them may have not treated HCV patients. The final sample included 
GIs, hepatologists and IDs. The selected physicians associated with 
these specialities were required to speak and/or read English.
survey instrument and data collection
The 14-page, self-completed questionnaire was adapted from modi-
fications from research conducted by Parkes et al (14) and included 
items designed to assess the workload, configuration and care processes 
of services in Canada to manage patients living with HCV. For the 
present study, the sample population was divided into three groups 
based on the type of service the physicians provided. Respondents 
were asked to choose from the following three categories: no role in 
the management and diagnosis of patients with HCV; diagnosis with 
or without initial investigations followed by referral to dedicated HCV 
service (diagnostic investigative provider [DIP]); and provision of a 
dedicated HCV service such as diagnosis, investigation, treatment 
and follow-up (comprehensive service provider [CSP]). Surveys were 
mailed to 528 physicians at their practice sites. A prenotification letter 
was sent one week before the survey package to notify the respond-
ents of the study. The first letter, which introduced the participants 
to the study, was mailed on January 25, 2007. The letter contained 
information outlining the objectives of the study as well as the affirma-
tion of confidentiality and how informed consent was obtained. This 
was followed by the survey package, which was sent on January 31, 
2007. Questionnaires were assigned code numbers and mailed with a 
cover letter to each potential respondent.
Participants were asked specific questions about providing treat-
ment to IDUs. One question asked, “Which of the following criteria 
do you consider in determining eligibility for treatment?” History of 
substance use/abuse was included in the list. Another question asked, 
“Which of the following patients with moderate/severe chronic hepa-
titis C are likely to receive treatment in your clinical practice? Please 
tick all that apply.” The list included continuing IDUs who regularly 
use needle exchanges, and ex-IDUs stable on substitution therapy. If 
the respondent indicated that they would provide treatment to the 
ex-IDUs stable on substitution therapy, they were asked to indicate 
how long the patient was required to be stable. They were also asked, 
“What were the main reasons for patients’ ineligibility?” Ongoing 
illicit drug abuse was included in the list of options.
Current IDUs were defined as individuals who had injected drugs in 
the past six months and persons with a history of substance use/abuse 
whose most recent injection occurred more than six months previously. 
Potential predictors of CSPs’ characteristics included physicians’ prac-
tice region (Atlantic, central, prairies or western Canada), physician 
type (hepatologist, GI or ID), age, sex, years in practice, size of com-
munity where they practice and practice type (eg, solo practice, multiple 
specialty group, academic and other). To permit meaningful compari-
sons, the variables were collapsed into broader groups in bivariate and 
multivariate logistic regression analyses. All analyses were performed 
using SAS version 9.1 (SAS Institute, USA).
ethics
The Human Investigation Committee of the Faculty of Medicine, 
Memorial University of Newfoundland (St John’s, Newfoundland and 
Labrador) approved the present study.
Results
Response rate
Of 528 eligible physicians, 222 returned completed questionnaires. 
The physician type of the 222 respondents were as follows: 119 GIs 
(54%), 78 IDs (35%) and 25 hepatologists (11%). Of the GIs, IDs and 
hepatologists who were sent a survey, 38.6%, 48.1% and 43.1%, 
respectively, replied. The overall response rate was approximately 
42%. There was no significant difference between respondents and non-
respondents among the three types of specialists. Of the 222 respondents, 
53 (23.9%) stated that they had no role in the management and diag-
nosis of HCV patients; 73 (32.8%) stated that they diagnosed and/or 
initially investigated HCV infection, then referred HCV patients to 
dedicated HCV service providers; and 96 (43.3%) reported that they 
provided dedicated HCV service to patients.
sociodemographic characteristics of hCv health care providers
The majority of the DIPs (56.16%) and CSPs (46.88%) were distrib-
uted in central Canada (Ontario and Quebec). The 73 DIPs included 
35 GIs (47.9%), 35 IDs (47.9%) and three hepatologists (4.1%). The 
96 CSPs consisted of 53 GIs (55.2%), 22 IDs (22.9%) and 21 hepa-
tologists (21.9%). The age range most represented by DIPs and CSPs 
was 40 to 49 years. Men represented 66.7% of the DIPs and 82.1% of 
the CSPs. Most of the DIPs had practised for 10 to 19 years, and CSPs 
had practised for more than 10 years. Both DIPs and CSPs practised in 
a community with a population of 100,000 to more than 500,000. The 
main practice type of DIPs was academic compared with most CSPs, 
who were in solo practices. The detailed sociodemographic character-
istics of HCV health care providers are summarized in Table 1.
The associations between the sociodemographic characteristics of 
CSPs and the likelihood to provide treatment to current IDUs infected 
with HCV are shown in Table 2. Only 19 CSPs (19.79%) were likely 
to provide treatment to a current IDU who uses a needle exchange on 
a regular basis. In bivariate analysis, factors associated with willingness 
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to provide treatment to current IDUs included physician type, ie, IDs 
versus non-IDs (OR 3.27 [95% CI 1.11 to 9.63]), size of community 
where they practice (OR 4.16 [95% CI 1.36 to 12.71] [population 
500,000 or greater versus less than 500,000]). Eighty-six CSPs 
(89.58%) were likely to provide treatment to a person with a history of 
substance use/abuse who was stable on substitution therapy. The 
results from the multivariate logistic regression analyses were consist-
ent with the bivariate analyses with respect to direction and magni-
tude of the associations. Only community size was significantly 
associated with providing treatment to current IDUs (OR 3.89 [95% 
CI 1.06 to 14.26] [population 500,000 or greater versus less than 
500,000]) after controlling for other confounding variables. The fac-
tors associated with providing treatment to persons with a history of 
substance abuse/use who were stable on substitution therapy were fur-
ther examined and did not result in statistically significant findings 
(Table 3).
disCussion
The current study evaluating the willingness of specialists to provide 
treatment to IDUs with HCV was unique. The majority of physicians 
who responded to the survey indicated that they would not provide 
HCV treatment to a current IDU who used a needle exchange on a 
regular basis. Low treatment uptake rates were also reported in other 
studies (15,16), even in HCV populations with no history of injection 
drug use. This pattern persists despite increasing evidence that IDUs 
have simliar compliance and treatment-response rates when compared 
with non-IDUs (5,7,17-20).
Results of the present study suggest that the majority of specialists 
(89.58%) were willing to treat a former IDU who was stable on substi-
tution therapy. However, these specialists would prefer that the patient 
was stable on substitution therapy for at least six months before they 
provided treatment. This expectation may be a result of the rule that 
patients must be free of recreational drug use for as long as six months 
before being considered for HCV therapy in some Canadian centres 
(21). This finding is consistent with one study (22) that revealed that 
most physicians withheld treatment from HCV-infected alcoholics or 
IDUs until a six-month period of abstinence had been achieved. 
However, some researchers (23) deem this to be an impractical condi-
tion considering the fact that patients with substance abuse disorders 
are subject to relapse.
In the present study, IDs reported a greater likelihood to provide 
treatment to current IDUs. The willingness of specialists to provide 
treatment can be influenced by environment-, patient- and disease-
related factors. Many studies have indicated that potential factors such 
as patient motivation and adherence (24), ongoing illicit drug/alcohol 
misuse, HCV RNA levels, fibrosis, hepatitis severity, comorbidities, 
psychosocial issues, susceptibility to side effects, risk of reinfection 
(25-27), insurance, access of service and patients’ willingness to accept 
treatment (28), all influence a physician’s decision on whether to 
provide treatment. A study conducted in Australia (23) reported that 
many physicians believed that HCV treatment should not be provided 
to IDUs because of concerns regarding adverse effects, adherence to 
treatment and reinfection with HCV. Fears such as compliance and 
reinfection surrounding provision of treatment to IDUs are not well 
substantiated, and it has been shown that IDUs can endure and bene-
fit from HCV treatment (7). Several studies (11,29-31) have shown 
no association between HCV treatment uptake and injection drug 
use. Therefore, it is important to assess each HCV-infected substance 
abuser individually because they differ considerably from one another. 
Finally, results of the present study suggest a need to focus on compli-
cated environment-, patient-, disease- and physician-related factors 
if we intend to improve access of health care to IDUs infected with 
HCV.
limitations
There are limitations in the present study. First, participation was 
voluntary and there may be bias associated with this approach. 
Although the response rate was higher than in other studies, it was 
lower than desired. We tried to improve the response rate and reduce 
respondent and nonrespondent bias by sending a prenotification card 
about the study and reminding the specialists to reply.
To understand the possible reasons of nonresponse and estimate the 
magnitude of biases associated with it, the nonrespondents were 
reassessed. From the initial list of 562 physicians, 25 were deemed ineli-
gible for the study due to the following reasons: return to sender (ie, 
moved or did not treat HCV patients); e-mailed to state that they did 
not treat HCV patients; or that they had retired. After the follow-up 
telephone call, nine physicians were found to be ineligible for the fol-
lowing reasons: did not treat HCV patients; no time to complete the 
survey; moved; on holiday; or on maternity leave. We conducted a 
post hoc telephone survey of a group of nonresponders (n=36). 
Unfortunately, we encountered several obstacles when telephoning: 
the phone number provided by the Canadian Medical Directory was a 
hospital and not a direct line to the physician; voice mail boxes were 
often full, so messages could not be left; and physicians were rarely 
spoken to directly. We suspect that a substantial number of the 
Table 1
Sociodemographic characteristics of hepatitis C health 
care providers (n=169)
Variable
DIPs (n=73) CSPs (n=96)
n % n %
Region (Canada)
   Atlantic* 4 5.48 13 13.54
   Central† 41 56.16 45 46.88
   Prairies‡ 24 32.88 12 12.50
   Western§ 4 5.48 26 27.08
Physician type
   Gastroenterologist 35 47.95 53 55.21
   Infectious diseases  
      specialist
35 47.95 22 22.92
   Hepatologist 3 4.11 21 21.88
Age group, years
   <39 22 30.14 15 15.63
   40–49 29 39.73 40 41.67
   50–59 16 21.92 28 29.17
   ≥60 6 8.22 12 12.50
   Missing data 0 0.00 1 1.04
Sex
   Male 48 65.75 78 81.25
   Female 24 32.88 17 17.71
   Missing data 1 1.37 1 1.04
Years in practice
   <5 15 20.55 7 7.29
   5–9 12 16.44 18 18.75
   10–19 24 32.88 37 38.54
   ≥20 19 26.03 33 34.38
   Missing data 3 4.11 1 1.04
Population of practice community
   ≤25,000 0 0.00 2 2.08
   >25,000 to <100,000 3 4.11 6 6.25
   ≥100,000 to <500,000 13 17.81 42 43.75
   ≥500,000 57 78.08 45 46.88
   Missing data 0 0.00 1 1.04
Practice type
   Solo 11 15.07 44 45.83
   Not solo 62 84.93 52 54.17
*Includes New Brunswick, Newfoundland and Labrador, Nova Scotia and 
Prince Edward Island; †Includes Quebec and Ontario; ‡Includes Alberta, 
Saskatchewan and Manitoba; §British Columbia. CSPs Comprehensive ser-
vice providers; DIPs Diagnostic investigative providers
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nonrespondents were either ineligible or never received our study 
questionnaires. Furthermore, there was no reason to suspect that phys-
icians treating HCV patients were less likely than those who were not 
to respond to this survey. Thus, the true adjusted response rate is likely 
higher than 42%. Unfortunately, we did not have sufficient informa-
tion to estimate the magnitude and direction of possible biases associ-
ated with nonparticipation.
Second, we only selected practitioners who were representative of 
the English-speaking specialists rather than all HCV-related health 
care providers. This reduced the number of eligible participants from 
721 to 562 and, therefore, did not provide a complete examination of 
HCV health care services and pathways throughout Canada, and 
Quebec in particular. Furthermore, the Territories (Nunavut, Yukon 
and the Northwest Territories) were excluded from the study, thus 
limiting the examination of geographical variation. Third, only 96 
specialists stated that they had a role in providing treatment; there-
fore, the sample size was relatively small. In addition, the data obtained 
from the surveys were self-reported and comprises the respondents’ 
estimates of the HCV-management conditions in their practice and 
their own behaviours, which were possibly inaccurate. We restricted 
the study to a limited number of specialists’ demographic factors and did 
not completely explore the role of all potential patient- and disease-
related factors.
Finally, we are aware that the Canadian consensus statement (12) 
was published shortly after our study was conducted. Thus, our study 
results cannot be interpreted as a measure of physicians’ adherence to 
the current guideline. Given the importance of this topic, it is neces-
sary to track change of physicians’ attitudes and practice over time.
ConClusions And FutuRe diReCtions
The attitudes of the physicians surveyed in the present study revealed 
a reluctance to provide HCV treatment to IDUs – even if they use a 
needle exchange. These findings emphasize the need for future 
research and delivery of services that address the complexity of care 
and treatment for people in marginalized social circumstances. 
Table 2
Characteristics of health care providers associated with providing treatment to current injection drug users infected with 
hepatitis C virus
Treatment, n (row %) bivariate analysis Multivariate analysis*
Provided Not provided OR (95% CI) P OR (95% CI) P
Total care providers 19 (19.79) 77 (80.21)
Region
   Noncentral 8 (15.69) 43 (84.31) 1 1
   Central 11 (24.44) 34 (75.56) 1.74 (0.63–4.80) 0.2857 1.93 (0.62–6.03) 0.2574
Physician type
   Noninfectious specialist 11 (14.86) 63 (85.14) 1 1
   Infectious specialist   8 (36.36) 14 (63.64) 3.27 (1.11–9.63) 0.0313 2.48 (0.72–8.58) 0.1512
Age group, years
   <50 13 (23.21) 43 (76.79) 1 1
   ≥50   6 (15.00) 34 (85.00) 0.58 (0.20–1.70) 0.3226 0.48 (0.12–1.88) 0.2924
Sex
   Male 15 (18.99) 64 (81.01) 1 1
   Female   4 (23.53) 13 (76.47) 1.31 (0.38–4.60) 0.7742 0.98 (0.24–4.01) 0.9727
Years in practice
   <10   5 (20.00) 20 (80.00) 1 1
   ≥10 14 (19.72) 57 (80.28) 0.98 (0.31–3.08) 0.9757 1.64 (0.39–6.83) 0.4977
Population of practice community
   <500,000  5 (9.80) 46 (90.20) 1 1
   ≥500,000 14 (31.11) 31 (68.89) 4.16 (1.36–12.71) 0.0125 3.89 (1.06–14.26) 0.0403
Solo practice
   No 14 (26.92) 38 (73.08) 1 1
   Yes   5 (11.36) 39 (88.64) 0.34 (0.11–1.03) 0.0573 0.70 (0.18–2.73) 0.6030
*Adjusted for region, physician type, age group, sex, years in practice and size of community where they practice and solo practice
Table 3
Characteristics of health care providers associated with 
providing treatment to a person with a history of 
substance abuse/use who is stable on substitution therapy
Treatment, n (row %) bivariate analysis
Provided
Not 
provided
OR  
(95% CI) P
Total care providers 86 (89.58) 10 (10.42)
Region
   Noncentral 47 (92.16) 4 (7.84) 1
   Central 39 (86.67) 6 (13.33) 0.55 (0.15–2.10) 0.3845
Physician type
  Noninfectious specialist 65 (87.84) 9 (12.16) 1
  Infectious specialist 21 (95.45) 1 (4.55) 2.91 (0.35–24.30) 0.3247
Age group, years
   <50 48 (85.71) 8 (14.29) 1
   ≥50 38 (95.00) 2 (5.00) 3.17 (0.64–15.79) 0.1589
Sex
   Male 71 (89.87) 8 (10.13) 1
   Female 15 (88.24) 2 (11.76) 0.85 (0.16–4.38) 0.8412
Years in practice
   <10 20 (80.00) 5 (20.00) 1
   ≥10 66 (92.96) 5 (7.04) 3.30 (0.87–12.56) 0.0800
Population of practice community
   <500,000 47 (92.16) 4 (7.84) 1
   ≥500,000 39 (86.67) 6 (13.33) 0.55 (0.15–2.10) 0.3845
Solo practice
   No 46 (88.46) 6 (11.54) 1
   Yes 40 (90.91) 4 (9.09) 1.30 (0.34–4.95) 0.6963
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Provision of services to HCV-infected substance users is a challenge 
and requires the integration of members of a comprehensive care team, 
which can comprise hepatologists, psychologists, psychiatrists, IDs, 
immunologists, nurse practitioners, and drug and alcohol addiction 
counsellors. However, an ideal HCV health care practice would 
demand that we adjust provision of care to take into account the sub-
culture of IDUs to more effectively deliver treatment to HCV-infected 
IDUs, thus helping to limit and reduce the spread of disease.
To obtain a complete account of HCV treatment in Canada, future 
studies need to evaluate the entire comprehensive care system that pro-
vides treatment to people living with HCV. It was suggested that adher-
ence to antiviral therapy would be increased if patients were enrolled in 
multidisciplinary programs in which there is collaboration between areas, 
such as addiction counselling and hepatology, to allow for thorough 
patient follow-up by the comprehensive care team (18). However, there is 
no evidence that physicians who are a part of a multidisciplinary team are 
more likely to provide treatment to HCV-infected IDUs than those in 
solo practice. For this reason, a more encompassing study needs to be 
conducted to examine the effectiveness of an integrated multidisciplinary 
HCV clinic and how it affects treatment uptake in the HCV-infected 
IDU population. 
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